Direct-Acting Oral Anticoagulants: A Comparative Study on Value and Pricing

By Staff Writer

October 6, 2023

The Inflation Reduction Act (IRA) has initiated a new era in drug pricing. Soon, the Centers for Medicare & Medicaid Services (CMS) in the U.S will negotiate prices for certain high-cost drugs. This includes direct-acting oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban (Xarelto). These were among the first 10 drugs selected for negotiation.

Clinical and Economic Comparisons

The Institute for Clinical and Economic Review (ICER) released a Special Report that examines these two drugs, primarily used for non-valvular atrial fibrillation (NVAF). They were compared to warfarin, the older standard therapy, and dabigatran, the first DOAC available as a generic medication. The study considered patient experiences, clinical effectiveness, and cost comparisons.

The findings indicate that DOACs improve outcomes for NVAF patients compared to warfarin. Both apixaban and rivaroxaban have shown small net benefits compared to warfarin. However, when compared to dabigatran, the benefits are comparable or small.



Considering the Pricing Aspect

To inform drug price negotiations, they have calculated price premiums at various cost-effectiveness thresholds for apixaban and rivaroxaban relative to warfarin and dabigatran. For instance, the annual price premium for apixaban relative to warfarin ranges from $1,260 at a threshold of $50,000/evLYG to $4,350 at $200,000/evLYG. However, rivaroxaban was not associated with health gains compared to dabigatran. Thus, not supporting a price premium above CMS pricing for dabigatran.

This information provides a foundation for CMS and other stakeholders to make informed decisions about the value and pricing of these important drugs.

Reference url

Recent Posts

NICE health technology evaluations
        

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

🌟 Are you ready to embrace a new era in health technology evaluations?

Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.

Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).

#SyenzaNews #HealthEconomics #MarketAccess

Canada Drug Agency Plan
          

Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030

🚀 Are you ready to explore the future of healthcare in Canada?

The newly launched **Canada Drug Agency Plan** aims to redefine how we approach drug and health technology decisions, focusing on anticipation, innovation, and transformation to boost health outcomes for all Canadians. This five-year strategic initiative captures essential insights needed for a healthier nation amid evolving pharmaceutical policies.

Curious how this plan could impact the healthcare landscape? Dive into the full article to learn more!

#SyenzaNews #HealthcarePolicy #HealthTech #Innovation

hepatitis C treatment options
       

VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options

🔍 Are you curious about the latest advancements in hepatitis C treatment options?

The groundbreaking VIETNARMS trial reveals that sofosbuvir-daclatasvir offers a comparable efficacy to sofosbuvir-velpatasvir while exploring innovative strategies that could reshape treatment accessibility and affordability. With cure rates exceeding 90%, these findings hold promise for improving outcomes, especially in underserved populations.

Dive into the full article to uncover how these developments could revolutionize hepatitis C care!

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.